← board
EDIT
Editas Medicine, Inc.distress 6/10 · elevated risk$2.72-2%today-34% from 52w high
Ophthalmology 1Rare / Genetic 1
Lead: Heterozygous Familial Hypercholesterolemia
Revenue
pre-revenue
Liquidity
$124M
Runway
0.9 yrs
Shares 1y
+9%
Price & events
+14.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.2%
1D
-5.6%
1W
-1.4%
1M
-15.3%
3M
+25.9%
6M
-21.4%
1Y
-51.5%
2Y
-93.3%
5Y
-96.2%
All
Overview
- Market Cap
- $266.31M
- Enterprise Value
- $189.83M
- Volume
- 106.46K
- 52 Week Range
- $1.67 – $4.15
- Total Shares
- 97.91M
- Float Shares
- 79.28M
- Short %
- 14.67%
- % Held by Insiders
- 0.17%
- % Held by Institutions
- 49.30%
- RVOL
- 0.04x
- Beta
- 2.10
Pipeline stages · 1 programs
EDIT-301
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-09 | Phase 1/2 | EDIT-301 | Transfusion Dependent Beta Thalassemia, Hemoglobinopathies, Thalassemia Major, Thalassemia Intermedia | 9 | active not recruiting |
| 2025-08 | Phase 1/2 | EDIT-301 | Sickle Cell Disease, Hemoglobinopathies | 45 | active not recruiting |
| 2025-05-23 | Phase 1/2 | EDIT-101 | Leber Congenital Amaurosis 10, Inherited Retinal Dystrophies, Eye Diseases, Hereditary, Retinal Disease, Retinal Degeneration, Vision Disorders, Eye Disorders Congenital | 34 | unknown |
Catalyst news & presentations · 11
- 2027Guided 40%readoutPhase 1EDIT-401 · Topline data from Part 1 of Phase 1/2 trialSEC 8-K
- by the end of 2026Guided 40%readoutPhase 1EDIT-401 · Early in vivo human proof-of-concept dataSEC 8-K
- later in 2026Guided 40%trial initiationsecondaryPhase 1/2EDIT-401 · Initiate first-in-human Phase 1/2 trialSEC 8-K
- 2026-08-11earningsEarningsEarnings releaseyahoo
- mid-2026regulatory submissionFiled (NDA/BLA)EDIT-401 · Submit CTN to TGA in AustraliaSEC 8-K
- October 9, 2025conferencedata presentationsecondaryEDIT-401 · In vivo preclinical proof-of-concept data presented at ESGCT 32nd Annual CongressSEC 8-K
- June 2025conferencedata presentationsecondaryHBG1/2 promoter editing therapy · Data presented at EHA 2025 Congress on in vivo HBG1/2 promoter editing in NHPs using tLNPSEC 8-K
- May 14, 2025conferencedata presentationsecondarytLNP delivering HBG1/2 editing cargo · Data presented at ASGCT annual meeting showing HBG1/2 promoter editing in HSCsSEC 8-K
- May 13, 2025conferencedata presentationsecondaryIn vivo proof of concept data for an undisclosed liver target presented at ASGCT annual meeting.SEC 8-K
- 2024-12-11trial discontinuedEnded previously announced process to partner or out-license reni-cel.SEC 8-K
- 2024-12-11trial discontinuedrenizgamglogene autogedtemcel · Discontinued clinical development of reni-cel for sickle cell disease and transfusion-dependent beta thalassemia.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-05-05Chardan CapitalBuy
- 2026-03-10Jones TradingHold → Buy
- 2026-03-09Chardan CapitalBuy
- 2025-09-05HC Wainwright & Co.Buy
- 2025-09-03Wells FargoEqual-Weight
- 2025-08-15HC Wainwright & Co.Buy
Competitors — Heterozygous Familial Hypercholesterolemia
Recent news
- 2026-07-22Form 144 Editas Medicine For: 22 July By Investing.com - Investing.com South Africa
- 2026-07-22Editas Medicine stock trades steady as gene-editing pipeline advances and cash runway extends - Ad-hoc-news.de
- 2026-07-22Editas Medicine, Inc. (NASDAQ:EDIT) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
- 2026-07-21Editas Medicine (EDIT) insider plans to sell 5,500 shares after RSU vesting - Stock Titan
- 2026-07-17Editas Medicine stock steadies as gene-editing pipeline advances after Q1 loss narrows - Ad-hoc-news.de
- 2026-07-17Editas Medicine (NASDAQ:EDIT) Share Price Passes Below Fifty Day Moving Average - What's Next? - MarketBeat
- 2026-06-28Price to sales forward of Editas Medicine, Inc. – NASDAQ:EDIT - TradingView
- 2026-06-26EDIT Forecast — Price Target — Prediction for 2027 - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.